dc.contributor.author | Webb, K | |
dc.contributor.author | Gothard, L | |
dc.contributor.author | Mohammed, K | |
dc.contributor.author | Kirby, AM | |
dc.contributor.author | Locke, I | |
dc.contributor.author | Somaiah, N | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-09-05T11:04:13Z | |
dc.date.available | 2023-09-05T11:04:13Z | |
dc.date.issued | 2023-09-01 | |
dc.identifier | S0936-6555(23)00219-4 | |
dc.identifier.citation | Clinical Oncology, 2023, 35 (9), pp. e469 - e477 | |
dc.identifier.issn | 0936-6555 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5953 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.doi | 10.1016/j.clon.2023.06.006 | |
dc.description.abstract | AIMS: For patients with locally advanced primary/recurrent breast cancer, radiotherapy is an effective treatment for locoregional control. 36 Gy in 6 Gy once-weekly fractions is a commonly used schedule, but there are no data comparing local control and toxicity between 36 Gy delivered once-weekly versus accelerated schedules of multiple 6 Gy fractions per week. This retrospective study compared local control rates and acute and late toxicity in patients undergoing 30-36 Gy in 6 Gy fractions over 6 weeks versus more accelerated schedules over 2-3 weeks for an unresected breast cancer. MATERIALS AND METHODS: Patients who received 30-36 Gy in 6 Gy fractions to an unresected breast cancer ± involved lymph nodes between December 2011 and August 2020 were identified. Patients were grouped into once-weekly versus accelerated fractionation schedules. Response rates, local control and toxicity data were analysed. RESULTS: In total, 109 patients were identified. The median follow-up duration was 46 months. Forty-seven patients (43%) received once-weekly fractions and 62 patients (57%) received accelerated fractionation schedules. There were no significant differences in baseline tumour characteristics between the groups. Eighty-seven per cent of patients had an objective (complete or partial) response (81% in the once-weekly group; 91% in the accelerated group). The median time to local progression was 23.5 months overall (95% confidence interval 17.8-29.2); 23.5 months (95% confidence interval 18.8-28.1) in the once-weekly group and 19.0 months (95% confidence interval 7.0-31.1) in the accelerated group (P = 0.99). Acute toxicity of any grade occurred in 75% of patients (76% in the once-weekly group; 74% in the accelerated group) and grade 3 toxicity occurred in 7% of patients (7% in the once-weekly group; 8% in the accelerated group). There were no associations between the groups and acute or late toxicity grade (P = 0.78 and P = 0.26, respectively), although one grade 4 late toxicity (skin radionecrosis) occurred in a patient who received five fractions a week and therefore this regimen is not recommended. Study limitations included a lack of statistical power analysis, the necessary grouping of all accelerated patients for analysis and a high rate of censored data. CONCLUSION: There were no apparent differences in response rate, time to local progression or toxicity between patients who received 30-36 Gy in 6 Gy fractions once-weekly compared with twice-weekly as palliative treatment for locally advanced breast cancer. This regimen appears to be a safe alternative and may be preferred by patients. | |
dc.format | Print-Electronic | |
dc.format.extent | e469 - e477 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE LONDON | |
dc.relation.ispartof | Clinical Oncology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Breast cancer | |
dc.subject | Hypofractionation | |
dc.subject | Palliative radiotherapy | |
dc.subject | Humans | |
dc.subject | Female | |
dc.subject | Breast Neoplasms | |
dc.subject | Palliative Care | |
dc.subject | Retrospective Studies | |
dc.subject | Dose Fractionation, Radiation | |
dc.subject | Treatment Outcome | |
dc.title | Locoregional control and toxicity following high-dose hypofractionated and accelerated palliative radiotherapy regimens in breast cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-06-06 | |
dc.date.updated | 2023-09-05T09:02:54Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.clon.2023.06.006 | |
rioxxterms.licenseref.startdate | 2023-09-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37422360 | |
pubs.issue | 9 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.clon.2023.06.006 | |
pubs.volume | 35 | |
icr.researchteam | Trans Breast Radiobiol | |
dc.contributor.icrauthor | Gothard, Lone | |
dc.contributor.icrauthor | Somaiah, Navita | |
icr.provenance | Deposited by Sanda Ghiurcusor (impersonating Dr Navita Somaiah) on 2023-09-05. Deposit type is initial. No. of files: 1. Files: Webb ESTRO abstract final.docx | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Dr Navita Somaiah) on 2023-09-05. Deposit type is subsequent. No. of files: 1. Files: 1-s2.0-S0936655523002194-main.pdf | |
icr.provenance | Deposited by Sanda Ghiurcusor (impersonating Dr Navita Somaiah) on 2023-09-05. Deposit type is subsequent. No. of files: 1. Files: Webb Estro Article.pdf | |